No Data
Xinjiang Baihuacun Pharmaceutical Group Co., Ltd. Report for the first quarter of 2025
Xinjiang Bai Hua Cun Pharma Tech (600721.SH): In the first quarter, the net income was 20.7209 million yuan, a year-on-year increase of 0.28%.
Glory Financial on April 25 reported that Xinjiang Bai Hua Cun Pharma Tech (600721.SH) disclosed its first quarter report for 2025, achieving revenue of 96.9172 million yuan, a year-on-year increase of 6.65%; the Net income attributable to the shareholders of the listed company was 20.7209 million yuan, a year-on-year increase of 0.28%; the basic EPS was 0.0540 yuan.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Baihua Pharmaceutical: 2024 Annual Report of Xinjiang Baihuacun Pharmaceutical Group Co., Ltd.
Baihua Pharmaceutical: Summary of the 2024 Annual Report of Xinjiang Baihuacun Pharmaceutical Group Co., Ltd.
